tirzepatide trial obesity without diabetes for Older Adults with Type 2 and Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials | Diabetes Therapy A trial emulation in Nature
Description
FDA and HHS taking action against telehealths compounded drug advertising
What microdosing looks like Rather than starting at 2.5 mg, a microdosing approach might begin at 1.0 to 1.5 mg and increase in smaller increments: This approach requires compounded tirzepatide since brand-name pens do not allow sub-2.5 mg dosing
Int J Pharm 1999
Observational studies of first-trimester GLP-1 exposure have not shown increased rates of major birth defects compared to unexposed pregnancies
Learn more: What is Zepbound
